Leerink Partners Starts Rhythm Pharmaceuticals (RYTM) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St futures recover as oil slides ahead of inflation test
- Oracle raises full year profit guidance, stock rises after hours
- Oil set for weekly gain of over 7% on supply disruptions; US diesel hits record high
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Rhythm Pharmaceuticals (RYTM) PT Raised to $102 at Leerink Partners
July 9, 2025 4:18 PM EDTLeerink Partners analyst Faisal Khurshid raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $102.00 (from $88.00) while maintaining a Outperform rating.
The analyst comments "We are updating our estimates for RYTM following this morning's disclosure of bivamelagon Ph 2 data in acquired... More
